BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Canbas Co., Ltd. 

2-2-1 Otemachi, Numazu City

Shizuoka    410-0801  Japan
Phone: 81-55-954-3666 Fax: 81-55-954-3668


SEARCH JOBS




Industry
Biotechnology

Segment
Drug Discovery





 Company News
Canbas Co., Ltd.: CBP501 Met Primary Endpoint of Phase II Study in Malignant Pleural Mesothelioma 6/4/2012 10:01:18 AM
Canbas Co., Ltd.' CBP501 Receives FDA Orphan Drug Designation for Malignant Mesothelioma 1/5/2012 9:59:04 AM
Canbas Co., Ltd. Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Malignant Pleural Mesothelioma 11/1/2011 9:22:42 AM
Canbas Co., Ltd. Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Non-Small Cell Lung Cancer 10/27/2011 10:27:51 AM
Canbas Co., Ltd.' Phase II Anti-Cancer Drug CBP501 Mechanisms Include Calmodulin Binding; CBS9106 Inhibits CRM1 4/5/2011 9:11:04 AM
Canbas Co., Ltd. to Present New Data on Phase II Clinical Candidate CBP501 Mechanism of Action and Novel CRM1 Inhibitor CBS9106 at American Association for Cancer Research Annual Meeting 3/17/2011 9:34:48 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE), Millennium: The Takeda Oncology Company And Canbas Co., Ltd.: CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer 7/7/2009 9:39:20 AM
Privately Held Drug Discovery Company, Canbas Co., Ltd. Raises $20 Million In 4th Round Financing 1/6/2006 11:00:45 AM